|
TMPJ-01471
|
Activin A Protein, Human, Mouse, Rat, Cynomolgus, Rhesus, Recombinant
Activin A,INHBA,Inhibin ...
|
Human/Mouse/Rat
|
HEK293 Cells
|
|
Activin and inhibin are two closely related protein complexes that have almost directly opposite biological effects. Activins, members of the TGF-beta superfamily, are disulfide-linked dimeric proteins originally purified from gonadal fluids as proteins that stimulated pituitary follicle stimulating hormone (FSH) release. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell developm... |
|
TMPJ-01015
|
INHBC Protein, Human, Recombinant (C-His)
Activin β-C Chain,Activin Bet...
|
Human
|
Human Cells
|
|
Inhibin beta C chain, also known as activin beta-C chain and INHBC, belongs to the TGF-beta family. INHBC forms a homodimeric or heterodimeric through association with alpha and beta subunits, linked by one or more disulfide bonds. Inhibins are heterodimers of one alpha and one beta subunit. Activins are homo- or heterodimers of beta subunits only. Inhibins/activins regulates many physiological processes, such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell ... |
|
TMPK-01426
|
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Ready,MHC
|
Human
|
HEK293
|
|
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. |
|
TMPK-01421
|
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*02:01,MHC,Peptide Ready
|
Human
|
HEK293
|
|
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. |
|
TMPK-01420
|
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01
|
Human
|
HEK293
|
|
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. |
|
TMPK-01419
|
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready
|
Human
|
HEK293 Cells
|
|
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. |
|
TMPK-01409
|
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,MHC,HLA-A
|
Human
|
HEK293
|
|
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. |
|
TMPK-01415
|
APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His)
Peptide Ready,HLA-A*02:01,MHC
|
Human
|
HEK293
|
|
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. |
|
TMPK-01425
|
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready
|
Human
|
HEK293
|
|
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. |
|
TMPK-01410
|
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A,MHC,Peptide Ready
|
Human
|
HEK293
|
|
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. |
|
TMPK-01422
|
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01
|
Human
|
HEK293 Cells
|
|
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. |
|
TMPK-01417
|
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Alpha-1-fetoprotein,HPAFP,A
|
Human
|
HEK293
|
|
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. |
|
TMPK-01427
|
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
C-K-RAS,K-RAS4B,GTPase Kra
|
Human
|
E. coli
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
|
TMPK-01434
|
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,CFC2,GTPase Kras,KRA
|
Human
|
HEK293
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
|
TMPK-01403
|
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-Ras 2,KI-RAS,CFC2,KRAS1,GTP...
|
Human
|
E. coli
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
|
TMPK-01448
|
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein, Human, MHC (E. coli, His & Avi)
MHC,LAGE-2,NY-ESO-1,ESO1CTAG,MY-ESO-1,CT
|
Human
|
E. coli
|
|
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. |
|
TMPK-01525
|
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3...
|
Human
|
HEK293
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
|
TMPK-01519
|
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi)
MHC,FETA,AFP,Alpha-feto,...
|
Human
|
HEK293
|
|
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. |
|
TMPK-01461
|
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KRAS,RASK2,K-Ras...
|
Human
|
HEK293
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
|
TMPK-01530
|
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,LMP-2,PSMB9,LMP2,Macropain cha
|
Human
|
HEK293
|
|
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... |
|
TMPK-01494
|
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi)
HLA-A,HLA-A*0101,HLA...
|
Human
|
HEK293
|
|
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. |
|
TMPK-01470
|
HLA-A*02:01&B2M&MAGE-A4 or MAGE-A8 (KVLEHVVRV) Monomer Protein, Human, MHC (His & Avi)
MAGE-A4 or MAGE-A8,M...
|
Human
|
HEK293
|
|
MAGE-A4 and MAGE-A8 are type I membes of the melanoma associated antigen (MAGE) family. The MAGE family is a large, highly conserved group of proteins that share a common MAGE homology domain. Both MAGE-A4 and MAGE-A8 antigen-presenting peptides can be presented by HLA-A*02:01. |
|
TMPK-01481
|
HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
svn 2B,svn-2B,Survivin-2B
|
Human
|
HEK293
|
|
Survivin-2B, a known splice variant of survivin, has been reported to promote cell death in some cancer cells, although it keeps prosurvival function in others.survivin-2B promoted autophagy and further regulated cell death by accumulating and stabilizing IKK alpha in the nucleus. |
|
TMPK-01446
|
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi)
MAGE1,MAGE1A,MAGE-1 ...
|
Human
|
HEK293
|
|
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. |
|
TMPK-01513
|
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT6.1,LAGE2A,MHC,CTAG1B,CTA
|
Human
|
HEK293
|
|
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. |
|
TMPK-01399
|
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS2A,NS3,KRAS2,CFC2,K-RA
|
Human
|
E. coli
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. |
|
TMPK-01404
|
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS,KRAS1,KRAS2,MHC,RA
|
Human
|
E. coli
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
|
TMPK-01467
|
HLA-A*02:01&B2M&HPV 16 E6 (KLPQLCTEL) Monomer Protein, Human, MHC (His & Avi)
HPV16,E6,Human papillomavirus typ...
|
Human
|
HEK293 Cells
|
|
Human papillomavirus (HPV) 16 infection is a necessary condition for the pathogenesis and development of cervical cancer. The E6 protein is expressed by the HPV16 E6 gene and promotes malignant phenotype transformation, which is an important mechanism for the occurrence and development of cervical cancer. |
|
TMPK-01479
|
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
NS3,KRAS1,K-Ras 2,K-RAS2A
|
Human
|
HEK293 Cells
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. |
|
TMPK-01520
|
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi)
Alpha-1-fetoprotein,AFP,HPA
|
Human
|
HEK293 Cells
|
|
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. |
|
TMPK-01444
|
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Tetramer Protein, Human, MHC (His & Avi)
MZ2-E,MAGE1A,MAGE-1 anti...
|
Human
|
HEK293 Cells
|
|
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. |
|
TMPK-01474
|
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi)
|
Human
|
HEK293 Cells
|
|
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. |
|
TMPK-01487
|
HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein, Human, MHC (His & Avi)
svn-2B,Survivin-2B,svn 2B
|
Human
|
HEK293
|
|
Survivin-2B, a known splice variant of survivin, has been reported to promote cell death in some cancer cells, although it keeps prosurvival function in others.survivin-2B promoted autophagy and further regulated cell death by accumulating and stabilizing IKK alpha in the nucleus. |
|
TMPK-01499
|
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein, Human, MHC (His & Avi)
ESO1CTAG,LAGE-2,CTAG1B,LA
|
Human
|
HEK293
|
|
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. |
|
TMPK-01509
|
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein, Human, MHC (His & Avi)
TRP53,HLA-A,TP53,LFS1,P53,MHC,FLJ92943,BCC...
|
Human
|
HEK293
|
|
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. |
|
TMPK-01549
|
HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer Protein, Human, MHC (His & Avi)
RMF,WAGR,MHC,GUD,NPHS4GUD,WT1,WT33,WIT-2,A...
|
Human
|
HEK293
|
|
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. |
|
TMPK-01543
|
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (His & Avi)
LAGE2A,ESO1CTAG,LAGE-2,C...
|
Human
|
HEK293
|
|
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. |
|
TMPK-01497
|
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
MY-ESO-1,MHC,ESO1CTAG,NY-ESO-1,CTAG1,L...
|
Human
|
HEK293
|
|
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. |
|
TMPK-01517
|
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, Human, MHC (His & Avi)
survivin variant 3 alpha...
|
Human
|
HEK293
|
|
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. |
|
TMPK-01551
|
HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer Protein, Human, MHC (His & Avi)
MHC I,ME20-M,Glycoprotein 100,gp100,P100,HLA0201
|
Human
|
HEK293
|
|
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100. |
|
TMPK-01405
|
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
KI-RAS,RASK2,K-Ras 2,MHC,KRA<...
|
Human
|
E. coli
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
|
TMPK-01521
|
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi)
MHC,Alpha-feto,AFPD,Alph...
|
Human
|
HEK293
|
|
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. |
|
TMPK-01428
|
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
CFC2,K-RAS4B,K-Ras 2,C-K-RAS,R
|
Human
|
E. coli
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
|
TMPK-01532
|
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein, Human, MHC (His & Avi)
Antigen NY-CO-13,BCC7,FLJ92943,HLA-A
|
Human
|
HEK293
|
|
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. |
|
TMPK-01436
|
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Alpha-1-fetoprotein,FETA,MHC,...
|
Human
|
HEK293
|
|
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. |
|
TMPK-01540
|
HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Tetramer Protein, Human, MHC (His & Avi)
HLA0201,P100,MHC I,gp100,Glycoprotein 100,ME20-M
|
Human
|
HEK293
|
|
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100. |
|
TMPK-01538
|
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,LFS1,Antigen NY-CO-13,HLA-A,B...
|
Human
|
HEK293
|
|
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. |
|
TMPK-01503
|
HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein, Human, MHC (His & Avi)
Macropain chain 7,LMP-2,RING12,LM...
|
Human
|
HEK293
|
|
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... |
|
TMPK-01460
|
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,K-RAS2A,KI-RAS,K-RAS...
|
Human
|
HEK293
|
|
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
|
TMPK-01478
|
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
AFP,FETA,Alpha-feto,HP
|
Human
|
HEK293 Cells
|
|
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. |
沪公网安备 31010602006700号